Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
8,583
Total Claims
$4.4M
Drug Cost
355
Beneficiaries
$12K
Cost/Patient
Risk Score Breakdown 37/100
Score components are additive. Read full methodology
Peer Comparison vs. 5,101 Rheumatology providers
+345%
Opioid rate vs peers
18.1% vs 4.1% avg
+107%
Cost per patient vs peers
$12K vs $6,039 avg
+60%
Brand preference vs peers
12.1% vs 7.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Opioid rate is 345% above Rheumatology peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
18.1%
Opioid Rate
1,552
Opioid Claims
$116K
Opioid Cost
21.3%
Long-Acting Rate
Brand vs Generic
Brand: 1,039 claims · $4.0M
Generic: 7,520 claims · $422K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Corticotropin | 18 | $1.4M |
| Upadacitinib | 69 | $453K |
| Adalimumab | 39 | $432K |
| Adalimumab | 20 | $231K |
| Penicillamine | 12 | $188K |
| Voclosporin | 12 | $172K |
| Etanercept | 20 | $152K |
| Adalimumab | 19 | $145K |
| Certolizumab Pegol | 15 | $110K |
| Etanercept | 11 | $84K |
| Ixekizumab | 11 | $79K |
| Auranofin | 36 | $72K |
| Oxycodone Hcl | 33 | $41K |
| Apixaban | 40 | $40K |
| Fluticasone/Umeclidin/Vilanter | 45 | $37K |
Prescribing Profile
Patient Profile
69
Avg Age
71%
Female
2.05
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About